Crossmark

Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-018-3132-3

Published Online: 2019-01-09

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Jingjing

Wang, Weiwei

Yang, Jian

Zhu, Xuequan

Feng, Lei

Xiao, Le

Wang, Gang
Funding

Funding for this research was provided by:

National Key Research&Development Program of China (2016YFC1307200)

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201607)

Dengfeng Talent Support Program of Beijing Municipal Administration of Hospitals (DFL20151801)
License Information

Text and Data Mining valid from 2019-01-09
More Information

Article History

Received: 11 February 2018

Accepted: 11 December 2018

First Online: 9 January 2019

Ethics approval and consent to participate

: This study is approved by the ethics review committee of the Beijing Anding Hospital (No. 2016–106, Beijing, China). All participants are free to withdraw at any time during the study.All participants will be recruited following an informed consent process involving an approved plain language statement and consent form.

: Not applicable.

: We have read and understood TRIALS’s policy on declaration of interests and we declare that we have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.